news
Pharma bodies confirm signing NDAs for no-deal Brexit plans
The DHSC has confirmed that several pharmaceutical industry bodies have agreed to NDAs regarding plans for a no-deal Brexit.
List view / Grid view
Brexit
news
Millions to be invested to prevent drug shortages for no-deal Brexit
A fund of almost £450 million has been announced by the UK Government to mitigate drug shortages in the event of a no-deal Brexit.
news
£3 million for no-deal Brexit medication transport
The DHSC has announced their plans for pharmaceutical transportation in the case of a no-deal Brexit.
article
Brexit-tech: overcoming post‑Brexit challenges by driving operational and cost efficiencies
As 31 October draws closer, organisations across all sectors are putting contingency plans in place for whatever the impact of Brexit may be. However, for pharmaceutical organisations already operating in a heavily regulated, highly competitive landscape, the future looks a lot more uncertain than for most. Here, Neal Singh discusses…
news
Government letter advises pharma industry for no-deal Brexit
The government has issued a letter to the pharmaceutical industry, outlining how to prepare for a no-deal Brexit.
news
Haseeb Ahmad has been named as the new president of ABPI
Haseeb Ahmad from Novartis Pharmaceuticals has been confirmed as the new president of the The Association of the British Pharmaceutical Industry (ABPI).
article
Is the pharma sector ready for a ‘no-deal’ Brexit?
With the UK bracing itself for a 'no-deal' Brexit or some other outcome that has not yet been determined, pharma experts discussed the potential effect of Brexit on the supply chain and how to best prepare for it against the upcoming deadline.
news
Brexit will have ‘minimal’ impact on R&D, expert says
Jonathan Sheffield, OBE, was presenting at the PING (Pharmaceutical Industry Network Group) Brexit Conference 2019 in Hertfordshire, UK...
news
No-deal Brexit could mean temporary medicines export ban
The Association of the British Pharmaceutical Industry has called for a temporary ban on drugs exports in the event of a no-deal Brexit to prevent the NHS being hit by shortages...
article
Preparing for a no-deal Brexit
The pharmaceutical industry has increasingly voiced its concerns about the possibility of a no-deal Brexit and its impact on supplies and access to medicines. Here, the European Medicines Agency (EMA) gives some last-minute advice to pharma companies ahead of March 2019.
article
European Pharmaceutical Review Issue 1 2019
In this issue we look at the challenges of shipping temperature-controlled products, the potential use of blockchain for pharma, and using MALDI-TOF for identification of peptides in suspected illegal medicinal products. The edition also includes articles on aseptic containment, legal advice on licensing negotiations and an In-Depth Focus article from…
news
Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering
Pharmapack Europe has released a ‘European drug delivery and packaging’ report, ahead of the event’s opening which highlights, major challenges and opportunities for the industry in the year ahead...
news
Pharma industry ‘call for action’ following Brexit vote
The pharma industry has called for the government to act to ensure that patients receive their medications in the case of a ‘no deal’ situation...
news
MHRA announces EU exit no-deal legislative proposals
Innovators should be able to get products to the UK market as quickly and simply as possible, according to the Medicines and Healthcare products Regulatory Agency...
article
Issue 6, 2018
In this issue: Navigating roadblocks to clinical success: decision-making from molecule to clinic, Raman spectroscopy for the qualitative analysis of falsified and substandard medicines, and an overview of risk assessments for elemental impurities: implementation of ICH Q3D guidelines.
